Since potent and specific MDM2 inhibitors activate only wild-type p53, their cellular activity is restricted to tumor cells with wild-type p53, suggesting the possibility that tumor cells can develop acquired resistance to MDM2 inhibitors by inactivating p53 [20–22]. This evidence concerns the gene TP53 and neoplasm.